391 related articles for article (PubMed ID: 29962812)
1. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.
Llop E; E Guerrero P; Duran A; Barrabés S; Massaguer A; José Ferri M; Albiol-Quer M; de Llorens R; Peracaula R
World J Gastroenterol; 2018 Jun; 24(24):2537-2554. PubMed ID: 29962812
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
[TBL] [Abstract][Full Text] [Related]
3. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
4. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
5. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
6. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
7. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
Caputo D; Caracciolo G
Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
[TBL] [Abstract][Full Text] [Related]
9. Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?
Babic A; Wolpin BM
Clin Chem; 2016 Feb; 62(2):307-9. PubMed ID: 26721295
[No Abstract] [Full Text] [Related]
10. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
11. Advances in pancreatic cancer research: moving towards early detection.
He XY; Yuan YZ
World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
[TBL] [Abstract][Full Text] [Related]
12. Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer.
Nigjeh EN; Chen R; Allen-Tamura Y; Brand RE; Brentnall TA; Pan S
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28627758
[TBL] [Abstract][Full Text] [Related]
13. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
14. Application of glycoscience to the early detection of pancreatic cancer.
Miyoshi E; Kamada Y
Cancer Sci; 2016 Oct; 107(10):1357-1362. PubMed ID: 27418030
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
16. Protein-metabolite panel for early-stage pancreatic cancer.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
[No Abstract] [Full Text] [Related]
17. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
[TBL] [Abstract][Full Text] [Related]
18. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.
Abbott KL; Lim JM; Wells L; Benigno BB; McDonald JF; Pierce M
Proteomics; 2010 Feb; 10(3):470-81. PubMed ID: 19953551
[TBL] [Abstract][Full Text] [Related]
19. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma.
Lenggenhager D; Bengs S; Fritsch R; Hussung S; Busenhart P; Endhardt K; Töpfer A; The FO; Bütikofer S; Gubler C; Scharl M; Morell B
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00395. PubMed ID: 34388137
[TBL] [Abstract][Full Text] [Related]
20. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma.
Pan S; Chen R; Tamura Y; Crispin DA; Lai LA; May DH; McIntosh MW; Goodlett DR; Brentnall TA
J Proteome Res; 2014 Mar; 13(3):1293-306. PubMed ID: 24471499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
